PP
TEVA icon

PagnatoKarp Partners’s Teva Pharmaceuticals TEVA Stock Holding History

PagnatoKarp Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,915
Closed -$245K – 140
2017
Q3 		$245K Buy
13,915
+3,206
+30% +$72.1K 0.06% 119
2017
Q2 		$356K Buy
10,709
+2,988
+39% +$92.5K 0.11% 103
2017
Q1 		$248K Buy
+7,721
New +$263K 0.07% 109

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

PagnatoKarp Partners's TEVA Position: Q4 2017 in Review

PagnatoKarp Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 13,915 shares — an estimated $245K sold.

PagnatoKarp Partners first reported a position in TEVA in Q1 2017 and held it in 3 quarters. The position peaked at $356K in Q2 2017. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • PagnatoKarp Partners reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • PagnatoKarp Partners sold 13,915 Teva Pharmaceuticals shares in Q4 2017, an estimated $245K.
  • PagnatoKarp Partners first reported a position in Teva Pharmaceuticals in Q1 2017 and held it in 3 quarters.
  • PagnatoKarp Partners's Teva Pharmaceuticals position peaked at $356K in Q2 2017.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on PagnatoKarp Partners's 13F filing for Q4 2017, filed 14 Feb 2018.